Cipla zooms 5% on 2.53% stake sale by Hamied family, Okasa Pharma

Promoters Shirin Hamied, Rumana Hamied, Samina Hamied and Okasa Pharma Private Limited have sold 2.53 per cent shares of Cipla for an undisclosed amount

Cipla
SI Reporter New Delhi
2 min read Last Updated : May 15 2024 | 10:29 AM IST
Shares of pharmaceutical giant Cipla gained up to 4.9 per cent at Rs 1,423.60 per share on the BSE in Wednesday’s intraday trade. The stock price surge came after the company informed the exchanges about a 2.53 per cent stake sale by its promoters.

Cipla in a filing stated that certain members of its promoter group are in total selling 2,04,50,375 shares of the company.

Promoters Shirin Hamied, Rumana Hamied, Samina Hamied and Okasa Pharma Private Limited have sold 2.53 per cent shares of Cipla for an undisclosed amount. This will be used for the purpose of creating liquidity for specific needs including philanthropy, the company said. 

“Post transaction, the entire promoter group (including Person Acting in Concert) continues to hold 31.67 per cent in the company and remains committed to the future of Cipla Limited,” the company said in a statement. 
 
Cipla's promoter group is looking to sell a 2.53 per cent stake in India's third-largest drugmaker via a block deal worth nearly $316 million, CNBC-TV18 reported on Tuesday, 
citing sources. 

The promoter group will sell its stake in Cipla at a per-share price range of Rs 1,289.5 to Rs 1,357.35, the report said. 

The price range of the proposed stake sale means it will be sold at no more than the value of the stock's last closing price, which was 4 per cent lower, at Rs 1,357.35.

Cipla recently reported a consolidated net profit of Rs 939.04 crore for the quarter ended March 31 (Q4) of the financial year 2023-24 (FY24). This was a 78.6 per cent surge in profit year-on-year (Y-o-Y) from Rs 525.65 crore. 

The company's profit fell 11 per cent quarter-on-quarter (Q-o-Q) from Rs 1,055.90 crore reported in Q3. Revenue from operations for the pharmaceutical firm was Rs 6,082.37 crore, a 7.3 per cent Y-o-Y growth from Rs 5,665.95 crore. Sequentially, however, revenue fell 6.5 per cent from Rs 6,505.66 crore.

At 09:55 AM the stock of the company was trading 3.65 per cent higher at Rs 1406.50 per share. By comparison the S&P BSE Sensex moved up by 0.23 per cent. 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CiplaStake saleBuzzing stocksMarkets Sensex NiftyPharma sector

First Published: May 15 2024 | 10:29 AM IST

Next Story